Janux Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technol...
Latest News
8 days ago · businesswire.com
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune DiseaseSAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux's proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo.
11 days ago · zacks.com
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue EstimatesJanux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.
2 months ago · businesswire.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.
3 months ago · zacks.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to KnowJanux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove JANX